🧪 #Laboratorios | Cada año se diagnostican en España más de 22.000 nuevos casos de cáncer de vejiga, un tumor históricamente más frecuente en hombres que cada vez afecta más a las mujeres

SOGUG Roche España Verónica Calderero Hospital Clínic Begoña Mellado
i.mtr.cool/ldgmgrdtjt

Proyecto 50:50 en Pamplona.
📅 Martes 4 de junio a partir de las 18,30 horas
En el Colegio Oficial de Médicos.
nuria lainez, Dra. María José Lecumberri, Jose Luis Perez-Gracia
Con la colaboración de Asociación Española Contra el Cáncer Navarra ALCER Navarra
Pacientes, familiares e interesad@, os esperamos!!!

SOGUG sala llena desde primera hora en la I reunión multidisciplinar de cáncer de vejiga SOGUG enhorabuena Arancha Glez del Alba Bego PValderrama

Association between enfortumab-vedotin related cutaneous reaction and serum albumin levels in patients with advanced #UrothelialCancer . Presentation by Hayato Yamamoto, MD. #AUA24 written coverage by Julian Chavarriaga University of Toronto > bit.ly/3JLMAEj

Tumor size reduction (≥10% ) resulting from pre-surgical systemic therapy predicts improved survival following cytoreductive nephrectomy. Presentation by Daniel Shapiro UW Urology. #AUA24 written coverage by Julian Chavarriaga > bit.ly/4drNDXp

👏👏👏👏

We are happy to share our new study published today Journal of Clinical Oncology (👉 ascopubs.org/doi/10.1200/JC…) on the role of NECTIN4 amplifications to predict responses to Enfortumab Vedotin treatment in metastatic urothelial cancer.
With a huge contribution of our multinational team we uncovered

#ASCO24 garnered a record number of abstract submissions!

Preview the abstract titles to see what will be presented or published at this year’s meeting and browse the meeting program to start planning your schedule ➡️ brnw.ch/21wJ8kD

Just out in ESMO open ESMO - Eur. Oncology With 44.0 months of median follow-up nivolumab/cabozantinib continues to outperform sunitinib in M1 clear cell RCC. The 3 VEGF/TKI combinations have more similarities than differences and track each other with longer follow up gbr01.safelinks.protection.outlook.com/?url=https%3A%…

Gracias por invitarnos

Great to be in Sitges! KN564 expectations for subsequent therapy numbers in adjuvant #kidneycancer pembrolizumab should be tempered because it is a moving target in how we capture it Tom Powles #IKCS2024 . So I think KN564 post therapy numbers are reasonable.

Adjuvant pembrolizumab shows a significant and clinically meaningful OS benefit in intermediate and high risk clear cell renal cancer for the 1st time (KN564). This further tips the balance towards giving adjuvant pembro in this setting NEJM Toni Choueiri, MD nejm.org/doi/full/10.10…

How to treat metastatic RCC and Urothelial carcinoma after progression on adjuvant IO ? Based upon available data. Very good slide for clinical decisions by Ursula Vogl ESMO - Eur. Oncology .

Data from the control arm of adjuvant bladder cancer trials (CM274 and Ambassador250) suggests ~35% get no further therapy after relapse (accounting for censoring). Excellent sites. Chemo is globally available. Regular CT follow should catch early & treat. Any easy explanations?

Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study:
⭕️Final CLEAR trial results: Lenvatinib+pembrolizumab reduces mortality risk by 21% vs sunitinib in advanced RCC.
⭕️While median OS is similar, the combo’s lower HR & tight 95% CI underscore its robust

Interesting results with CD70-targeted CAR T cells in renal cell carcinoma are being presented #AACR24 and it's a pleasure to hear the discussant mention two of our articles on this therapeutic modality: nature.com/articles/s4157… and nature.com/articles/s4157…

New data from EV302 Enfortumab Vedotin & pembrolizumab for upper tract disease (~25% of pts). UTUC has distinct biological features including more FGFR alterations. PFS & OS HR of 0.50 & 0.53 respectively in the subset is in line with the whole population (0.45 and 0.47) #EAU24

Hoy se celebra el #DíaMundialDeLaActividadFísica 👇🏻